An unknown buyer completed the acquisition of 3.44% stake in ICU Medical, Inc. (NasdaqGS : ICUI) from Smiths Group International Holdings Ltd. for $88.042 million.
February 28, 2024
Share
An unknown buyer acquired 3.44% stake in ICU Medical, Inc. (NasdaqGS : ICUI) from Smiths Group International Holdings Ltd. for $88.042 million on February 29, 2024. the proceeds from the sale will be used for general corporate purposes. Smiths continues to hold 1,670,000 shares in ICU Medical representing approximately 6.92% of ICU Medical's issued share capital. J.P. Morgan Securities LLC acted as broker for sale.
An unknown buyer completed the acquisition of 3.44% stake in ICU Medical, Inc. (NasdaqGS : ICUI) from Smiths Group International Holdings Ltd. for $88.042 million on February 29, 2024.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
An unknown buyer completed the acquisition of 3.44% stake in ICU Medical, Inc. (NasdaqGS : ICUI) from Smiths Group International Holdings Ltd. for $88.042 million.
ICU MEDICAL, INC. 
